

Author/ Year	Population	Depression scales	Biomarkers	Intervention
Baune et al., 2021 [11]	N randomized: 119 N analyzed: 99 Age: about 47 Diagnose: major depression severe to moderate (76% resistant)	Diagnose: DMS-IV and MADRS Outcome: MADRS	basal CRP-hs	Substance: celecoxib + vortioxetine or placebo + vortioxetine Dose: 400 mg/day Time: 8 weeks
Halaris et al., 2020 [12]	N randomized: 65 N analyzed: 47 Age: 20-65 Diagnose: bipolar depression I/II treatment resistant	Diagnose: DSM-IV and HAM-D-17 Outcome: HAM-D-17	Not analyzed	Substance: celecoxib + escitalopram or placebo + escitalopram Dose: celecoxib 200 mg/2x/day escitalopram 10 mg/2x/day Time: 10 weeks
Edberg et al., 2018 [13]	N randomized: 64 N analyzed: 47 Age: 21-65 Diagnose: bipolar depression treatment resistant and health control (n= 35)	Diagnose: DSM-IV and HAM-D-17 Outcome: HAM-D-17	CRP and IL-6	Substance: celecoxib + escitalopram or placebo + escitalopram Dose: celecoxib 200 mg/2x/day escitalopram 10 mg/2x/day Time: 8 weeks
Abbasi et al., 2012 [14]	N randomized: 40 N analyzed: 37 Age: 18-50 Diagnose: major depression	Diagnose: DSM-IV-TR and HAM-D-17 Outcome: HAM-D-17	IL-6	Substance: celecoxib + sertraline or placebo + sertraline Dose: celecoxib 200mg/day sertraline 200mg/day Time: 6 weeks

Ra ison et al., 2013 [9]	N randomized: 60 N analyzed: 52 Age: 25-60 Diagnose: major depression unipolar and bipolar treatment resistant	Diagnose: DSM-IV Outcome: HAM-D-17	CRP-hs e TNF- alpha	Substance: infliximab or placebo (+ ATU) Dose: 5mg/kg/120 minutes IV Time: semana 0, 2 e 6
McIntyre et al., 2019 [10]	N randomized: 60 N analyzed: 47 Age: 18-65 Diagnose: TAB I/II in depressive fase	Diagnose: DSM-5 Outcome: MARS	CRP	Substance: infliximab or placebo (+ ATU) Dose: 5mg/kg/120 minutes IV Time: semana 0, 2 e 6
Mansur et al., 2020 [15]	N randomized: 55 N analyzed: 43 Age: 18-65 Diagnose: TAB I/II in depressive fase	Diagnose: DSM-5 Outcome: MADRS and CTQ	TNFR1, TNFR2, NF-kB, c-Myc, FADD, IKKalpha/betha	Substance: infliximab or placebo (+ ATU) Dose: 5mg/kg/120 minutes IV Time: semana 0, 2 e 6

Chart 1. Methodological details of selected studies: population, depression scales, biomarkers and intervention

ATU= antidepressant treatment in use; **BAI**= Beck Anxiety Scale; **BDI**= Beck Depression Scale; **BDNF**= Brain-derived neurotrophic factor; **BPRS**= Brief Psychiatric Rating Scale; **CRP**= C-reactive protein; **CTQ**= Childhood Trauma Questionnaire; **c-Myc**= Master Regulator of Cell Cycle Entry and Proliferative Metabolism; **DSM-IV**= Diagnostic and Statistical Manual of Mental Disorders IV; **DSM-IV-TR**= Diagnostic and Statistical Manual of Mental Disorders IV revised text; **DSM-5**= Diagnostic and Statistical Manual of Mental Disorders V; **FADD**= Fas-associated death domain protein; **IKKalpha/betha**= Kinases inhibitory- κ B kinase; **HAM-D-17**= 17-Item Hamilton Depression Scale; **IL**= Interleukins; **IV**= intravenous; **MADRS**= Montgomery-Asberg Depression Scale; **NF- κ B**= Nuclear factor kappa B; **CRP-hs**= Ultrasensitive C-reactive Protein; **Q-LES-Q**= Life Pleasure and Satisfaction Questionnaire; **MDD**= Major Depressive Disorder; **TNFR**= Tumor Necrosis Factor Receptor; **TNF-alpha**= Tumor Necrosis Factor Alpha.